Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 58 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H2 2016', provides an overview of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- The report reviews pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) therapeutics and enlists all their major and minor projects
- The report assesses Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Overview 6
Therapeutics Development 7
Pipeline Products for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Overview 7
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Therapeutics under Development by Companies 8
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Products under Development by Companies 12
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Companies Involved in Therapeutics Development 13
CSL Limited 13
GeNeuro SA 14
Mitsubishi Tanabe Pharma Corporation 15
Octapharma AG 16
Pfizer Inc. 17
Shire Plc 18
Teijin Pharma Limited 19
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
(hyaluronidase (human) (recombinant) + immune globulin (human)) - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
fingolimod hydrochloride - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
GL-2045 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
GNbAC-1 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
immune globulin (human) - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
immune globulin (human) - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
immune globulin (human) - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
immune globulin (human) - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Dormant Projects 52
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Product Development Milestones 53
Featured News & Press Releases 53
Aug 10, 2015: Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder 53
Apr 04, 2013: CSL Behring's Privigen Obtains European Approval For Treatment Of Chronic Inflammatory Demyelinating Polyneuropathy 53
Feb 21, 2013: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For CSL Behring's Privigen 54
Jun 27, 2012: PRIMA Study Shows Treatment With Privigen Improved Function In Patients With Chronic Inflammatory Demyelinating Polyneuropathy 54
May 30, 2012: CSL Behring Submits Marketing Authorization Variation Application To EMA For Privigen In Chronic Inflammatory Demyelinating Polyradiculoneuropathy 55
Mar 26, 2012: CSL Behring Enrolls First Patient In PATH Trial To Evaluate Hizentra For Treatment Of CIDP 56
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 57
Disclaimer 58

List of Tables

Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by CSL Limited, H2 2016 13
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by GeNeuro SA, H2 2016 14
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 15
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Octapharma AG, H2 2016 16
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Pfizer Inc., H2 2016 17
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Shire Plc, H2 2016 18
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Teijin Pharma Limited, H2 2016 19
Assessment by Monotherapy Products, H2 2016 20
Assessment by Combination Products, H2 2016 21
Number of Products by Stage and Target, H2 2016 23
Number of Products by Stage and Mechanism of Action, H2 2016 24
Number of Products by Stage and Route of Administration, H2 2016 26
Number of Products by Stage and Molecule Type, H2 2016 28
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Dormant Projects, H2 2016 52